Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

207.32 +0.65 (+0.31%)

Streaming Delayed Price Updated: 10:22 AM EST, Nov 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

99 100 Next >

Biotech Stocks Stay Strong Through A Period Of Uncertainty In The Market ↗

February 24, 2025

Many analysts are feeling better about the prospects for healthcare stocks in 2025.

Via Talk Markets

Topics ETFs Stocks / Equities

2 Very Healthy High-Yield Dividend Stocks to Buy for a Safe and Growing Passive Income Stream ↗

February 24, 2025

Via The Motley Fool

Buy This Ultra-Safe High-Yield Dividend King Stock for Reliable Passive Income ↗

February 21, 2025

Via The Motley Fool

NVIDIA's New AI System Aims To Transform Genetic Research With Unmatched Speed And Precision ↗

February 20, 2025

NVIDIA (NASDAQ: NVDA) has introduced Evo 2, an advanced artificial intelligence (AI) system aimed at transforming the field of biological research.

Via Benzinga

Topics Artificial Intelligence

Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports ↗

February 19, 2025

Trump's proposed 25% tariffs on auto, semiconductor, and pharmaceutical imports have rattled markets and could affect ETFs with heavy exposure to these sectors.

Via Benzinga

Topics ETFs Government World Trade

P/E Ratio Insights for Johnson & Johnson ↗

February 12, 2025

Via Benzinga

Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst ↗

February 18, 2025

Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025.

Via Benzinga

Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich ↗

February 18, 2025

Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion.

Via Benzinga

Topics Government

Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study ↗

February 13, 2025

Sanofi and J&J halted a phase 3 E. coli vaccine trial due to insufficient efficacy. Sanofi's Q4 2024 IFRS EPS dropped by €0.15 following a $250M charge.

Via Benzinga

Congress Member Josh Gottheimer Dumps Nvidia, Microsoft, Loads Up On Tesla Stocks Instead ↗

February 12, 2025

Josh Gottheimer disclosed dozens of recent stock transactions including selling Nvidia stock and buying Tesla stock.

Via Benzinga

What's a Fair Price to Buy Johnson & Johnson Stock? ↗

February 12, 2025

Via The Motley Fool

2 Stocks to Buy if There Is a Market Crash in 2025 ↗

February 09, 2025

Via The Motley Fool

Johnson & Johnson Explores Sale of Stroke Device Maker Cerenovus As MedTech Overhaul Accelerates ↗

February 12, 2025

Johnson & Johnson is considering selling its stroke care unit, Cerenovus, in a potential $1 billion deal as part of its ongoing efforts to refine its medtech division.

Via Benzinga

Warren Buffett's Granddaughter Claimed He Cut Her Off And She Couldn't Afford Health Insurance: 'He Disowned My Twin Sister And Myself' ↗

February 09, 2025

Via Benzinga

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗

February 08, 2025

Via The Motley Fool

Topics Stocks

Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years ↗

February 07, 2025

On Friday, Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

Via Benzinga

(JNJ) - Analyzing Johnson & Johnson's Short Interest ↗

February 06, 2025

Via Benzinga

Kenvue's Q4 Sales Miss, Margins Improve ↗

February 06, 2025

Kenvue posted mixed Q4 earnings, with in-line EPS but revenue below estimates, driven by challenges in its Skin Health and Beauty segment.

Via The Motley Fool

Topics Earnings

Is Johnson & Johnson Stock a Buy? ↗

February 02, 2025

Via The Motley Fool

Johnson & Johnson's Options Frenzy: What You Need to Know ↗

January 30, 2025

Via Benzinga

Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q4 Results Tomorrow

February 05, 2025

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results tomorrow before the bell. Here’s what you need to know.

Via StockStory

What To Expect From Eli Lilly’s (LLY) Q4 Earnings

February 05, 2025

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow morning. Here’s what to expect.

Via StockStory

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Logility Supply Chain Solutions, Inc. (Nasdaq - LGTY), Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Shutterstock, Inc. (NYSE - SSTK)

February 04, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference

February 03, 2025

From Johnson & Johnson

Via Business Wire

Can Biotech Stocks Survive The Precarious Macro? ↗

February 03, 2025

We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows.

Via Talk Markets

Topics Stocks / Equities World Trade

Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now

February 03, 2025

Teva Pharmaceuticals is the world's largest generic drug maker with over 500 generics in its portfolio, but shares sold off on its recent earnings, buying opp?

Via MarketBeat

Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around? ↗

February 01, 2025

Via The Motley Fool

Did Johnson & Johnson Just Give Investors 23 Billion Reasons to Buy Its Stock? ↗

February 01, 2025

Via The Motley Fool

The Dogs Of The Dow 2025 ↗

January 31, 2025

The Dogs of the Dow is an investing strategy well-known to retail and institutional investors.

Via Talk Markets

Topics Stocks Stocks / Equities

Johnson & Johnson (NYSE:JNJ) Posts Q4 Sales In Line With Estimates

January 31, 2025

Multinational healthcare company Johnson & Johnson (NYSE:JNJ) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 5.3% year on year to $22.52 billion. Its non-GAAP profit of $2.04 per...

Via StockStory

Topics Artificial Intelligence Intellectual Property

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.